Last reviewed · How we verify
NCT00034216
Collection of Blood From Patients With Cancer
trial in Prostate Cancer in 1,750 participants. Currently enrolling.
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,750 |
| Start date | 16 July 2002 |
| Sites | 1 location across United States |
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Breast Cancer — all drugs for Breast Cancer →
- Colon Cancer — all drugs for Colon Cancer →
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
National Cancer Institute (NCI)
Who can join
18 and older, any sex, with Prostate Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression.
Rice CM, Davies LC, Subleski JJ, Maio N, et al · · 2018 · cited 276× · PMID 30504842 · DOI 10.1038/s41467-018-07505-2 -
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.
Wang L, Balasubramanian P, Chen AP, Kummar S, et al · · 2016 · cited 98× · PMID 27663478 · DOI 10.1053/j.seminoncol.2016.06.004 -
Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells.
Lu D, Graf RP, Harvey M, Madan RA, et al · · 2015 · cited 10× · PMID 28936240 · DOI 10.5772/60745 -
Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.
Zhang L, Troccoli CI, Mateo-Victoriano B, Misiara Lincheta L, et al · · 2025 · cited 3× · PMID 39388307 · DOI 10.1158/0008-5472.can-24-0133 -
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Li C, Madan RA, Lee MJ, Lee S, et al · · 2026 · PMID 41881502 · DOI 10.1136/jitc-2025-014365
Verify or expand the search:
- PubMed search for NCT00034216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00034216 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00034216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing